Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic,
auto-immune process that leads to vision loss. While steroids are effective in the short
term, the side-effect profile of chronic steroid use necessitates the identification of
effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the
signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate
whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.